47 related articles for article (PubMed ID: 26111606)
21. Iron metabolism and haemoglobin formation in the embryonated hen egg. 3. Iron in the liver and blood of the hatching chick.
RAMSAY WN
Biochem J; 1952 Jun; 51(3):289-91. PubMed ID: 12977726
[No Abstract] [Full Text] [Related]
22. [Intravenous iron therapy].
Med Contemp; 1952 May; 70(5):299-301. PubMed ID: 14956388
[No Abstract] [Full Text] [Related]
23. Intravenous iron therapy.
VARIAVA NS
Antiseptic; 1952 Mar; 49(3):210-7. PubMed ID: 14934073
[No Abstract] [Full Text] [Related]
24. [Blood protein modifications after oral and intravenous iron load].
VALENTE R
Rass Fisiopatol Clin Ter; 1951; 23(2-12):355-69. PubMed ID: 14930263
[No Abstract] [Full Text] [Related]
25. Hartmut Derendorf's work on tissue distribution.
Vozmediano V; Müller M; Schmidt S
Eur J Pharm Sci; 2019 Aug; 136():104977. PubMed ID: 31254643
[No Abstract] [Full Text] [Related]
26. Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics.
Funk F; Flühmann B; Barton AE
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216261
[TBL] [Abstract][Full Text] [Related]
27. Bioequivalence decision for nanoparticular iron complex drugs for parenteral administration based on their disposition.
Schnorr J; Fütterer S; Spicher K; Catarinolo M; Schlösser C; Enzmann H; Langguth P
Regul Toxicol Pharmacol; 2018 Apr; 94():293-298. PubMed ID: 29454888
[TBL] [Abstract][Full Text] [Related]
28. Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach.
Neu HM; Alexishin SA; Brandis JEP; Williams AMC; Li W; Sun D; Zheng N; Jiang W; Zimrin A; Fink JC; Polli JE; Kane MA; Michel SLJ
Mol Pharm; 2019 Mar; 16(3):1272-1281. PubMed ID: 30676753
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate.
Brandis JEP; Kihn KC; Taraban MB; Schnorr J; Confer AM; Batelu S; Sun D; Rodriguez JD; Jiang W; Goldberg DP; Langguth P; Stemmler TL; Yu YB; Kane MA; Polli JE; Michel SLJ
Mol Pharm; 2021 Apr; 18(4):1544-1557. PubMed ID: 33621099
[TBL] [Abstract][Full Text] [Related]
30. Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: From production to clinical practice.
Nikravesh N; Borchard G; Hofmann H; Philipp E; Flühmann B; Wick P
Nanomedicine; 2020 Jun; 26():102178. PubMed ID: 32145382
[TBL] [Abstract][Full Text] [Related]
31. Differences in tissue distribution of iron from various clinically used intravenous iron complexes in fetal avian heart and liver.
Spicher K; Brendler-Schwaab S; Schlösser C; Catarinolo M; Fütterer S; Langguth P; Enzmann H
Regul Toxicol Pharmacol; 2015 Oct; 73(1):65-72. PubMed ID: 26111606
[TBL] [Abstract][Full Text] [Related]
32. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
Mühlebach S
Adv Drug Deliv Rev; 2018 Jun; 131():122-131. PubMed ID: 29966685
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
